Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y2Y6
UPID:
TMM98_HUMAN
Alternative names:
Protein TADA1
Alternative UPACC:
Q9Y2Y6; E1P631; Q9UFK2
Background:
Transmembrane protein 98, also known as Protein TADA1, plays a crucial role in the regulation of oligodendrocyte differentiation and myelination. It functions as a negative regulator of MYRF, a key factor in myelin gene expression, by inhibiting MYRF self-cleavage and nuclear translocation. Additionally, its secreted form is instrumental in promoting Th1 cell differentiation.
Therapeutic significance:
Transmembrane protein 98's involvement in Nanophthalmos 4, a rare eye development disorder, underscores its potential as a therapeutic target. Understanding the role of Transmembrane protein 98 could open doors to potential therapeutic strategies for treating this condition and enhancing our knowledge of eye development and myelination processes.